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1. Introduction 
The mechanism of arthritis including rheumatoid arthritis (RA) has not been clarified 
enough in terms of its molecular biology. However, owing to advances in techniques to 
produce monoclonal antibodies and genetic engineering techniques to produce recombinant 
proteins, targeted therapies have progressed. Tumor necrosis factor-alpha (TNF-), 
interleukin-1 (IL-1), interleukin-6 (IL-6), and T-cells (CD28) are representative targets, and 
therapies targeting them have produced epoch-making results in the treatment of RA. In 
this text, we report the role and effects of therapy with adrenomedullin as a novel, 
promising targeted therapy.  
Adrenomedullin (ADM) is a peptide that was discovered by the assay-based monitoring of 
platelet cAMP activity (Kitamura et al., 1993). This protein shows not only marked 
vasodilatory but also in vivo and in vitro anti-inflammatory activities (Isumi et al., 1998). 
To determine the efficacy of ADM in patients with RA, we researched the plasma level of 
ADM and its correlation with the plasma CRP level. The result showed that the plasma 
ADM level in patients with RA was twice that in healthy controls and strongly correlated 
with the blood CRP level, and the ADM level in synovial tissue in patients with RA was 3 
times that in patients with osteoarthritis (Chosa et al., 2003). Then, thorough research is 
needed to examine whether the cultured RA synoviocytes are related to the ADM in vitro. 
The result showed that ADM was produced from RA synoviocytes and reduced the IL-6 
level in cultured media (Fig. 5). These results suggest the close involvement of ADM in 
arthritis in RA. Therefore, to examine the therapeutic efficacy of intra-articular ADM 
injection, we injected ADM into the joint of a rabbit model of adjuvant arthritis, and 
confirmed the inhibition of arthritis at an early stage. These findings suggest the 
potentiality of ADM as a novel drug for the treatment of arthritis in RA (Okura et al., 
2008). 
2. Measured adrenomedullin (ADM) in patients with RA 
2.1 Patient background 
For measurement of plasma ADM, the study population consisted of 26 patients with RA 
aged 58–73 years (mean ± SD 62 ± 4 yrs), 10 with osteoarthritis (OA) aged 59–76 years  
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(68 ±8), and 10 healthy volunteer controls aged 50–66 years (57 ± 5). All subjects were  
female. 
To clarify further the reason for the increase in plasma ADM, joint fluid, synovial tissue, and 
cartilage were measured by radioimmunoassay (RIA). These were acquired from surgical 
subjects during total knee arthroplasty in patients with RA (n = 6) and OA (n = 6). All 
patients with RA were classified as stage 4, functional class 2, according to the criteria of the 
American Rheumatism Association (ARA) (Clegg & Ward, 1987); they were medicated with 
only DMARDs and NSAIDs without steroid. All patients with OA were classified as stage 4 
to 5, according to the Kellgren-Lawrence radiographic staging system (Kellgren & 
Lawrence, 1958). Since plasma ADM concentration has been reported to be elevated in 
patients with hypertension, renal failure, systemic infections, myocardial infarction, and 
heart failure (Ishimitsu et al., 1994; Nishikimi et al., 1995; Kobayashi et al., 1996), patients 
and controls with these conditions were excluded. 
2.2 Methods of measuring ADM levels in plasma, joint fluid and joint tissues 
2.2.1 Methods measuring the plasma and joint fluid ADM level  
Blood and joint fluid samples were transferred into tubes containing 1 mg/ml EDTA-2Na 
and 500 kallikrein inhibitory units/ml of aprotinin for measurement of ADM. The plasma 
was kept at –30°C until assayed. Levels of plasma ADM and joint fluid ADM were 
measured by IRMA using specific kits (AM RIA Shionogi) developed by Shionogi 
Pharmaceutical Co. Ltd., Osaka, Japan. The limit of detection of human AM is 0.5 pmol/l for 
these kits.  
2.2.2 Extraction of ADM in joint tissues 
For measuring ADM levels of acquired joint fluids, samples were acidified with acetic acid 
to a final concentration of 1.0 M and centrifuged at 3000 rpm for 5 min, while synovium and 
cartilage specimens were acidified with acetic acid to a final concentration of 1.0 M and 
boiled for 10 min to inactivate proteases. The samples were then homogenized and 
centrifuged for 90 min at 12,000 rpm. The supernatant of samples was applied to a Sep-Pak 
C18 cartridge (Millipore-Waters, Milford, MA, USA). After the cartridge was washed with 
10% CH3CN in 0.1% trifluoroacetic acid, the absorbed materials were eluted with 50% 
CH3CN in 0.1% trifluoroacetic acid. The eluted samples were dried by speed vacuum, 
freeze-dried and stored at –30°C until assayed. 
2.2.3 Radioimmunoassay for ADM  
The RIA for ADM was performed as described previously (Kitamura et al., 1994). The 
incubation buffer for RIA was 0.05 M sodium phosphate buffer (pH 7.4), containing 0.5% 
BSA, 0.5% Triton X-100, 0.08 M NaCl, 0.025 M EDTA 2Na, 0.05% NaN3, and 500 KIU/ml 
trasylol. A disposable plastic tube (10 × 75 mm) was used for assaying. All assay procedures 
were performed at 4°C. Both standard ADM and unknown samples (100 μl) were incubated 
with anti-ADM antiserum diluent (200 μl) for 12 h before the tracer solution (125I-AM, 
18,000–20,000 counts/min in 100 μl) was added. After incubation for 16 h, anti-rabbit IgG 
goat serum diluent (100 μl) was added. After standing for 24 h, the tubes were centrifuged at 
3000 rpm for 30 min at 4°C and the radioactivity of the precipitate was measured using an 
Aloka ARC-600 gamma counter. 
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2.3 Result of ADM in plasma, joint fluid and joint tissues in patients with RA 
Discussion of joint ADM level in patients with RA 
It has been reported that some collagenous disorders show increased levels of plasma ADM 
(Yudoh et al., 1999). We measured and compared plasma ADM concentrations in patients 
with RA and healthy controls, finding that patients with RA exhibited a 1.7-fold increase in 
plasma ADM levels (Table 1). 
 
 Tolal ADM (fmol / ml) Mature ADM (fmol / ml) 
Healthy controls  11.64±2.8 1.34±0.9 
RA patients  18.35±6.9 1.80±1.4 
OA patients  12.88±1.9 1.42±0.8 
Table 1. Blood adrenomedullin (ADM) levels in RA and OA patients and healthy controls 
All values are expressed as means ± SD.※p < 0.01. Patients with RA demonstrated high 
plasma concentration of ADM (18.35 ± 6.9 fmol/ml) compared to healthy controls (11.64 ± 
2.8 fmol/ml) and OA patients (12.88 ± 1.9 fmol/ml)  
Moreover, plasma ADM levels in patients with RA were also found to be significantly 
correlated to CRP levels (Fig. 1). In RA, CRP correlates with disease activity and response to 
therapy. Our patient data did not include RA disease activity, excluding RA functional class 
classification. Hamada et al. (2010) stated that no autologous antibody such as rheumatoid 
factor or anti-CCP antibody showed significant correlation with plasma ADM level. In 
addition, there was no correlation with disease activity scores such as DAS-28. DAS-28 is not 
only dependent on the inflammatory level, so the plasma ADM level may escalate before 
escalation of the activity in synovitis or the amount of actual synovial inflammation 
(Hamada et al., 2010). Therefore, our results suggest that ADM levels are increased in 
patients with RA and investigated that they might be correlated with disease activity. 
Moreover, ADM concentration in the joint fluid of RA patients (10.8 ± 4.3 fmol/ml) was 
significantly higher than that of OA patients (7.2 ± 1.8 fmol/ml) (Fig. 2).  
 
 
Fig. 1. Correlation between plasma AM and C-reactive protein 
A significant positive correlation was observed between AM and CRP (correlation 
coefficient = 0.685, p < 0.01). Plasma ADM and plasma CRP levels were found to be well 
correlated. The correlation coefficient between CRP and AM was 0.685, p < 0.01.  
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Fig. 2. Concentration of ADM between RA and OA in plasma and joint fluid  
Patients with RA demonstrated high plasma concentration of ADM (18.35 ± 6.9 fmol/ml) 
compared to OA patients (12.88 ± 1.9 fmol/ml). ADM concentration in the joint fluid of RA 
patients (10.8 ± 4.3 fmol/ml) was significantly higher than that of OA patients (7.2 ± 1.8 
fmol/ml)  
We applied conventional radioimmunoassay (RIA) to determine ADM concentration in 
tissues. RA is characterized by the presence of inflammatory synovitis accompanied by 
destruction of joint cartilage and bone. The concentration of ADM in the synovium of RA 
patients was 3.2-fold higher than that of OA patients (Fig. 3). In addition, the concentration 
of ADM in plasma of RA patients was 1.4-fold higher than that of OA patients (Table 2). To 
determine the relationship between plasma ADM and arthritis in patients with RA, we 
compared ADM levels in joint fluid of RA and OA patients. Joint fluid is similar in 
composition to plasma, which explains the similarly significant increases in ADM 
concentration in both plasma and joint fluid in patients with RA compared with those with 
OA (p < 0.01) (Fig. 2). These observations indicate that the reason for this high concentration 
of ADM might be secretion from synovial stromal cells or secretion from synovial vascular 
wall cells. However, the mechanism by which plasma and joint fluid ADM levels increase in 
patients with RA remains unknown.  
Several tissues including vessels secrete ADM, and elevated ADM could conceivably be 
caused by secretion from vascular cells in general. When we consider the results, in which 
ADM levels in the synovium of RA patients were higher than those of OA patients, we may 
assume that synovitis is one reason for the increased ADM concentration in synovium and 
joint fluid, and may partially contribute to the increase in ADM levels in plasma. Our results 
indicate the possibility that ADM participates in the pathophysiology of joint lesions in 
patients with RA. Together with the fact that ADM is known to inhibit the secretion of 
cytokines from several cell lines (Isumi et al., 1999; Kamoi et al., 1995), the findings seem to 
validate the assumption that production and secretion of ADM in synovium are strongly 
correlated with anti-inflammation in arthritis. Thus, the elevation of plasma ADM levels 
may be related to the anti-inflammatory response. Clementi et al. (1999) investigated the 
anti-inflammatory effect of ADM in rats, finding that ADM production in several cell lines 
was strongly induced by stimulation of a group of inflammatory cytokines including 
interleukin 1 and tumor necrosis factor-ǂ (TNF-ǂ) (Hofbauer et al., 2002). Some studies 
report that ADM acts as a circulating vasoactive hormone in blood, and plays an anti-
inflammatory role in the prevention of local infection and inflammation, thus contributing 
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to host defense systems (Ueda et al., 1999; Elsasser & Kahl, 2002). From these observations, 
we speculate that ADM may play a role in the pathophysiology of inflammation as well as 
in the regulation of joint disorders.  
Synovitis inevitably plays a role in the destruction of joint surface, so we measured the 
concentration of ADM in articular cartilage. We found the ADM concentration in cartilage 
was lower than that of other tissues (Fig. 2). While the concentration of ADM in normal 
human articular cartilage has not been determined, an immunohistochemical study has 
reported that normal human articular chondrocytes produce ADM (Fig. 4) (Asada et al., 
1999). No statistically significant difference was found in the articular cartilage 
concentration of ADM in RA and OA patients (Fig. 3). We therefore speculate that this may 
be because our samples were from cases that consisted of end-stage arthritis, with advanced 
degeneration and differentiation of the cartilage. A thorough investigation of the role of 
ADM in cartilage pathophysiology is necessary.  
 
 
Fig. 3. Concentration of ADM for synovium and articular cartilage in patients with OA and RA 
RA patients showed higher concentrations of ADM in synovium compared to OA patients. 
*p < 0.01; **not significant. In cartilage, there is no significantly difference between the 
concentration of OA and RA  
 
 
Fig. 4. Novel distribution of adrenomedullin-immunoreactive cells in human cartilage 
Hyaline cartilage: Chondrocytes are positive for ADM. (donated from Prof. Asada, Miyazaki 
University) 
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We observed that plasma ADM concentration in patients with RA was higher than that of 
healthy controls, and plasma ADM and plasma CRP levels were found to be well correlated. 
Our data suggest that plasma ADM levels increase with the activity of RA. We conclude that 
ADM probably plays a part in the regulation of the inflammatory process of RA, and its 
plasma and/or joint fluid levels could be used as an index of the degree of RA. Therefore, 
we investigated the role of ADM in inflammation in cultured RA synoviocytes (fibroblast-
like synovium) in a subsequent investigation.  
3. Effiency of ADM in cultured synovia (fibroblast-like synoviocytes)  
3.1 Methods of ADM study in cultured FLS  
3.1.1 Fibroblast-like synoviocytes (FLS) culture 
Synovial tissue specimens were collected under sterile conditions from 6 patients with 
RA. Specimen collection occurred during total knee arthroplasty in all patients with RA. 
All RA patients fulfilled 1987 American College of Rheumatology criteria for RA. All of 
them were treated with only NSAIDs, DMARDs and hyaluronic acid injection into the 
joint before samples were obtained. The methods of FLS culture was described previously 
(Nanki, et al., 2001).  
3.1.2 Characterization of secreted ADM 
To examine the molecular forms of ADM, extracts of cells cultured on a 100-mm dish and 15 
ml of the conditioned medium (1%FBS) were analyzed by reverse-phase high-performance 
liquid chromatography (HPLC) with a column of TSK ODS 120 A (Tosoh, Tokyo, Japan). A 
linear gradient of 10% to 60% acetonitrile was run in 0.1% trifluoroacetic acid for 60 minutes 
and the ir-AM level in each fraction was measured by RIA. The recovery of ir-ADM from 
this HPLC system was greater than 80%. 
3.2 IL-6 secretion was inhibited in cultured FLS after addition of ADM 
The present study demonstrated that cultured RA synoviocytes expressed the mRNA for 
ADM and also actively secreted ADM (Fig. 5). The active secretion of ADM by RA 
synoviocytes seems to be similar to its active secretion by endothelial cells (Hojo et al., 2001; 
Uemura et al., 2002). ADM in the culture medium seemed to be actual AM because reverse-
phase HPLC revealed that most of the ADM secreted into the medium emerged at the  
 
 
Fig. 5. Time course curve for secretion of AM and intracellular ADM  
The cells were incubated for the indicated time-periods in serum free medium, and the 
ADM was determined by RIA. Intracellular ADM was too low to be determined. 
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identical elution position to that of authentic human ADM (1-52), which is the full-length 
human ADM peptide (Fig. 6). The minor peak that was eluted earlier was thought to be 
oxidized ADM containing methione sulfoxide. The intracellular ADM concentration 
remained extremely low in RA synoviocytes (Fig. 5), suggesting that these cells 
constitutively secrete ADM. Thus, RA synoviocytes seem to secrete ADM rapidly after its 
synthesis, with little intracellular storage.  
 
 
Fig. 6. Analysis by reverse-phase HPLC of immunoreactive adrenomedullin (ir-ADM) 
secreted into the media  
A linear gradient of acetonitrile of 10% to 60% was made in 0.1% trifluoroacetic acid for 60 
minutes at a flow rate of 1.0mL/min. The arrow indicates the elution position of synthetic 
human AM. The specificity of the RIA was clarified. 
 
 
Fig. 7. Inhibitory effect of ADM about the IL-6 secretion into the media in cultured FLS  
Effects of ADM 22-52 10-6M (ADM blocker) on control level of IL-6 secretion in cultured 
fibroblast like synoviocytes (FLS) donated from RA patients. Serum-starved FLS were 
incubated 24 hours. Values are the means±SEM of six wells examined. Each was compared 
with the cells incubated with 1%FBS media (control). Each set of experiments was repeated 
three times and identical results were obtained.  
When the synoviocytes reached confluence, ADM (10-8 M) was added to the culture media. 
After 24 hours, the level of IL-6 in culture media significantly decreased. Moreover, ADM 
(22-52), which is an ADM antagonist, elevated the level of IL-6 in culture media (Fig. 7). 
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These observations lead us to conclude that ADM inhibited the secretion of IL-6 and 
regulated the IL-6 production in the cultured RA synoviocytes.  
Besides the findings in our study, a similar report stated that ADM reduced constitutive 
production of IL6 from RA synoviocytes in a dose-dependent manner. A high concentration 
of ADM (>10-8 mmol/l) significantly reduced constitutive production of IL6 compared with 
a low concentration of ADM (<10-9 mmol/l) (p=0.0029) (Nanke et al., 2003). Then, we tried 
to inject ADM into the knee in antigen-induced arthritis in rabbits. 
4. Adrenomedullin injection to the knee in antigen-induced arthritis (AIA) in 
rabbits 
4.1 Methods 
4.1.1 Induction of antigen-induced arthritis 
The AIA rabbit model was developed as described by Consden and colleagues (Consden et 
al., 1971). Briefly, rabbits were anesthetized by an intravenous injection of pentobarbital 
sodium and were immunized by 1.2 ml intradermal injections of 6 mg/ml ovalbumin 
(Sigma-Aldrich, St Louis, MO, USA) in saline emulsified with an equal volume of TiterMax 
Gold (TiterMax, Norcross, GA, USA). The rabbits were re-immunized in the same manner 
30 days later. Seven days after the second immunization, the rabbits underwent skin testing 
following a 0.1 ml intradermal injection of a solution of 200 μg/ml ovalbumin in saline. 
Animals exhibiting a welt of 13 mm or greater after 24 hours were confirmed as 
'immunized'. Twelve days after the second immunization, the 'immunized' rabbits were 
anesthetized and arthritis was induced by 0.5 ml bilateral knee intra-articular injections of a 
solution of 20 mg/ml ovalbumin in saline. 
4.1.2 Treatment protocol 
Twenty-four hours after arthritis induction, the rabbits were anesthetized and different 
doses of ADM (1 ng to 3 μg; Peptide Institute Inc., Osaka, Japan) dissolved in 0.3 ml saline 
were injected into the knee joint spaces or 0.3 ml saline was injected into the contralateral 
knee joint spaces as controls. For time-course experiments, ADM and saline were injected 
into the knee joint spaces daily for 7 days and 20 days. The rabbits were sacrificed on day 8 
(n = 5 in each group) and day 21 (n = 3 in each group). 
4.1.3 Joint swelling 
To evaluate the grade of arthritis/inflammation, joint swelling was assessed by measuring 
the maximum diameter of the swollen joint using calipers. The swelling was compared with 
that at the same level on the contralateral knee, treated with saline. 
4.1.4 Histological evaluation 
For histological evaluation, rabbits were given an overdose of pentobarbital 8 days and 21 
days after arthritis induction. The infrapatellar fat pads were harvested from dissected 
knees and were cut longitudinally, perpendicular to the patella ligament in the middle of 
the infrapatellar fat pad. The tissues were fixed in 10% buffered formaldehyde and 
embedded in paraffin wax, and sections 3 μm thick were obtained. The specimens were 
stained with H & E and Mallory–Azan stains. The area of the infrapatellar fat pad was 
measured using AxioVision software (release 4.3; ZEISS, Oberkochen, Germany). 
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Inflammatory cells, including lymphocytes and plasma cells, were counted in the 
superficial and deep portions of the infrapatellar fat pads (three fields under ×200 
magnification in each portion) in H & E-stained specimens. The inflammatory cell count 
was performed by two independent observers. 
To measure the collagen volume, the images of sections with Mallory–Azan stain were 
projected onto a color imaging analysis system (Mac SCOPE version 2.3.2; Mitani, Fukui, 
Japan). In each section, 10 separate sites were analyzed at ×40 magnification. The collagen 
volume fraction was obtained by calculating the mean ratio of connective tissue to the total 
tissue area. 
4.1.5 Measurement of cytokine mRNA 
Total RNA was extracted from the infrapatellar fat pad with TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer's protocol and was then reverse-
transcribed into cDNA with the SuperScript First-Strand Synthesis System for RT-PCR kit 
(Invitrogen). To measure rabbit TNFǂ, IL-6, vascular endothelial growth factor (VEGF), 
transforming growth factor beta (TGFǃ), and ǃ-actin mRNA levels, we used the quantitative 
RT-PCR method of real-time quantitative PCR. 
4.2 Result after joint injection of ADM in AIA rabbit 
4.2.1 Adrenomedullin concentration in plasma  
We measured the plasma ADM concentration before and 15, 30, 60 and 120 minutes after 
intra-articular injection of 3 μg ADM (n = 6). No significant change, however, was observed 
in the plasma concentration of ADM (Figure (Figure1).1). The intra-articular injection of 
ADM did not therefore increase the level of ADM in plasma. 
 
 
Fig. 8. Sequential concentrations of plasma ADM following intra-articular ADM injection in 
rabbits with antigen-induced arthritis.  
Whole-blood samples (total 1 ml) were taken from a peripheral artery in the rabbit ear using 
a 22-gauge needle before and 15, 30, 60 and 120 minutes after intra-articular injection of 3 μg 
www.intechopen.com
 Rheumatoid Arthritis – Treatment 182 
adrenomedullin (AM). The plasma AM concentration was measured using an 
immunoenzymometric assay kit (n = 6). White circles, plasma AM levels in rabbits; black 
circles, average plasma AM levels at each time point after intra-articular injection of 3 μg 
AM. Data expressed as the mean ± SEM. Each of plasma ADM level was not significantly. 
4.2.2 Joint swelling 
To evaluate the anti-inflammatory effect of ADM on arthritis, we used calipers to measure 
joint swelling in ADM-treated knees and compared the swelling with that at the same level 
on the contralateral knees, treated with saline. In rabbits with AIA treated with daily 
injections of ADM or saline into the knee joint spaces for 7 days, 3 μg ADM significantly 
reduced joint swelling compared with contralateral knees after day 5. No significant 
decrease in joint swelling was observed, however, in knees treated with <0.1 μg ADM (Fig. 
9a and 10).  
 
 
Fig. 9. Adrenomedullin reduced joint swelling in rabbits with antigen-induced arthritis.  
(a) Joint swelling progress in rabbits with AIA treated with daily intra-articular injections of 
ADM or saline for 7 days (n = 5 in each group). Daily intra-articular injections of 3 μg ADM 
significantly decreased joint swelling compared with contralateral knees after day 5. No 
significant decrease in joint swelling was observed in knees treated with <0.1 μg ADM.  
(b) Joint swelling progress in rabbits with AIA treated with daily intra-articular injections of 
ADM or saline for 20 days (n = 3 in each group). Daily intra-articular injections of 0.1 μg and 
3 μg ADM showed a tendency to reduce joint swelling throughout the experiment, and 
significantly decreased joint swelling on days 12 and 16 and on days 8, 12 and 16, 
respectively, compared with contralateral control knees. Daily intra-articular injections of 1 
ng and 0.01 μg ADM did not ameliorate joint swelling throughout the experiments (data not 
shown). Data expressed as the mean ± standard error of the mean. *P < 0.05 and **P < 0.01, 
compared with contralateral knees. 
In rabbits with AIA treated for 20 days with daily injections of ADM or saline into the 
knee joint spaces, 0.1 μg and 3 μg ADM showed a tendency to reduce joint swelling 
throughout the experiment – and significantly decreased joint swelling on days 12 and 16 
and on days 8, 12 and 16, respectively, compared with contralateral knees (Fig. 9b). Daily 
intra-articular injections of 1 ng and 0.01 μg ADM, however, did not ameliorate joint 
swelling (data not shown). 
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Fig. 10. Macroscopic pathology of joint swelling in rabbits with antigen-induced arthritis  
(a) Photograph taken before arthritis onset. (b) Photograph taken 24 hours after arthritis 
onset. (c) The left knee of the rabbit with antigen-induced arthritis (AIA) was treated with 
daily intra-articular injections of 1 ng ADM for 7 days and the right knee was treated with 
daily intra-articular injections of saline for 7 days. Photograph taken 8 days after arthritis 
onset. (d) The left knee of the rabbit with AIA was treated with daily intra-articular 
injections of 3 μg ADM for 7 days and the right knee was treated with daily intra-articular 
injections of saline for 7 days. Photograph taken 8 days after arthritis onset. 
4.2.3 Histological findings 
The infrapatellar fat pads harvested from control knees on day 8 showed a dense 
inflammatory reaction, including edematous changes in the synovial interstitium, 
intracellular edema in the infrapatellar fat pads, hyperplasia of synovial surface cells and 
widespread infiltration of inflammatory cells in the infrapatellar fat pads (Fig. 11d,e,f). In 
contrast, these inflammatory reactions were suppressed in the knees treated with ADM 
for 7 days. In particular, edematous changes in the synovial interstitium, intracellular 
edema in the infrapatellar fat pads and infiltration of inflammatory cells in the deep 
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portion of the infrapatellar fat pads were significantly reduced (Fig. 11a,b,c). The 
infrapatellar fat pads harvested from control knees on day 21 also showed a severe 
inflammatory reaction. Edematous changes in the synovial interstitium, hyperplasia of 
synovial surface cells and widespread infiltration of inflammatory cells throughout the 
infrapatellar fat pads were observed (Fig. 12d,e,f). In the knees treated with ADM for 20 
days, these inflammatory reactions were ameliorated. ADM treatment significantly 
suppressed infiltration of inflammatory cells in the deep portion of the infrapatellar fat 
pads (Fig. 12a,b,c). 
 
 
Fig. 11. Histological analysis of infrapatellar fat pad harvested from rabbit knees 8 days after 
arthritis onset  
Rabbits with antigen-induced arthritis (AIA) were treated with daily injections of ADM or 
saline (control) into the knee joint spaces for 7 days. Tissues were sectioned longitudinally 
perpendicular to the patella ligament in the middle of the tissue, and were stained with H & 
E. (a), (b), (c) AIA rabbit knee was treated with daily intra-articular injections of 3 μg ADM 
for 7 days. (a) Low-magnification image (×100). (b), (c) High-magnification images (×400) of 
the superficial portion and the deep portion of (a), respectively. (d), (e), and (f) the 
contralateral knee of (a), (b) and (c) was treated with daily intra-articular injections of saline 
for 7 days. (d) Low-magnification image (×100). (e), (f) High-magnification images (×400) of 
the superficial portion and the deep portion of (d), respectively. Arrows indicate 
inflammatory cells. Bar = 50 μm. 
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Fig. 12. Histological analysis of infrapatellar fat pad harvested from rabbit knees 21 days 
after arthritis onset  
Rabbits with antigen-induced arthritis (AIA) were treated with daily injections of ADM or 
saline (control) into the knee joint spaces for 20 days. (a), (b), (c) AIA rabbit knee was 
treated with daily intra-articular injections of 3 μg AM for 20 days. (a) Low-magnification 
image (×100). (b), (c) High-magnification images (×400) of the superficial portion and the 
deep portion of (a), respectively. (d), (e), and (f) the contralateral knee of (a), (b) and (c) 
was treated with daily intra-articular injections of saline for 20 days. (d) Low-
magnification image (×100). (e), (f) High-magnification images (×400) of the superficial 
portion and the deep portion of (d), respectively. Arrows indicate inflammatory cells. Bar 
= 50 μm. 
4.2.4 Collagen volume in infrapatella fat pads treated with Adrenomedullin 
To observe the effect of ADM on fibrosis of the infrapatellar fat pads harvested on day 21, 
we examined the collagen volume ratio of the infrapatellar fat pad histologically using 
Mallory–Azan staining. The collagen volume ratio was significantly increased in ADM-
treated knees by 39% and 31% at 0.1 μg and 3 μg ADM, respectively, compared with control 
knees (Fig. 13 and 14). The effects of ADM on these pathological tissue changes, however, 
were not observed in knees treated with low-dose ADM. 
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Fig. 13. Histological analysis of infrapatellar fat-pad sections stained with Mallory – Azan 
from rabbits with antigen-induced arthritis 
The tissues were sectioned longitudinally perpendicular to the patella ligament in the 
middle of the tissue, and were stained with Mallory – Azan. (a) AIA rabbit knee was treated 
with daily intra-articular injections of 3 μg ADM for 20 days. (b) AIA rabbit knee was 
treated with daily intra-articular injections of 1 ng ADM for 20 days. (c) The contralateral 
knee of (a) was treated with daily intra-articular injections of saline for 20 days. Photographs 
taken at ×40 magnification. Bar = 500 μm. 
 
 
Fig. 14. Quantitative evaluation of collagen volume in the infrapatellar fat pad  
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The collagen volume ratio was increased in ADM-treated knees by 39% and 31% at 0.1 μg 
and 3 μg ADM, respectively. Data expressed as the mean ± standard error of the mean. *P < 
0.05, compared with contralateral knees. 
4.2.5 Cytokines 
To elucidate the mechanism of the anti-inflammatory effects of AM in inflamed joints, we 
investigated the effect of AM on cytokine mRNA expression linked to AIA. Treatment with 
AM reduced TNFǂ mRNA expression in a dose-dependent manner. Daily intra-articular 
injections of 3 μg AM significantly suppressed the TNFǂ mRNA level by 21% and 49% at 
day 8 and day 21, respectively, compared with controls (Fig. 15a). In contrast, AM dose-
dependently increased IL-6 mRNA expression. Daily intra-articular injections of 3 μg AM 
significantly increased the IL-6 mRNA level by 45% and 121% at day 8 and day 21, 
respectively, compared with controls (Fig. 15b). Although the VEGF mRNA level was 
suppressed by 10% at 3 μg AM on day 8, we did not observe a dose-dependent effect of AM 
on VEGF mRNA expression (Fig. 15d). AM treatment did not significantly alter the TGFǃ 
mRNA level (Fig. 15c).  
 
 
 
 
Fig. 15. Effect of adrenomedullin on cytokine mRNA expression linked to antigen-induced 
arthritis  
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Expression levels of TNFǂ, IL-6, transforming growth factor beta (TGFǃ), and vascular 
endothelial growth factor (VEGF) mRNA in the infrapatellar fat pads were determined by 
real-time quantitative PCR. (a) ADM treatment reduced TNFǂ mRNA expression in a dose-
dependent manner. Daily intra-articular injections of 3 μg ADM significantly suppressed the 
TNFǂ mRNA level by 21% and 49% at day 8 and day 21, respectively. (b) ADM increased 
IL-6 mRNA expression in a dose-dependent manner. Daily intra-articular injections of 3 μg 
AM significantly increased the IL-6 mRNA level by 45% and 121% at day 8 and day 21, 
respectively. (c) ADM treatment did not alter the TGFǃ mRNA level. (d) Although the VEGF 
mRNA level was suppressed by 10% at 3 μg AM on day 8, a dose-dependent effect of ADM 
on VEGF mRNA expression was not observed. Open and closed columns represent the data 
at day 8 (n = 5 in each group) and day 21 (n = 3 in each group), respectively. Data expressed 
as the mean ± SEM. *P < 0.05 and **P < 0.01, compared with contralateral knees 
4.3 Therapeutic efficacy of ADM injection to the knee in AIA in rabbits 
In the present study we have shown that daily injections of ADM into the knee joint spaces 
of rabbits with AIA ameliorated the inflammatory response associated with the disease. 
Treatment with ADM reduced joint swelling, and reduced the expression of TNFǂ mRNA, 
edematous changes and the number of infiltrating inflammatory cells in the synovial tissue.  
We observed that ADM suppressed joint swelling (Fig. 9 and 10). Histologically, ADM 
treatment reduced edematous changes and increased the ratio of connective tissue in the 
infrapatellar fat pad (Fig. 13 and 14). A previous study showed that TNFǂ induced 
cytoskeletal reorganization of endothelial cells and increased endothelial permeability by 
stimulating TNF receptors 1 and 2 (Ferrero et al., 2001). In addition, TNFǂ facilitates the 
ability of VEGF to promote excessive vascular permeability (Clauss et al., 2001). TNFǂ also 
suppresses the expression of matrix genes and the induction of connective tissue growth 
factor by TGFǃ during the wound healing response (Leask & Abraham, 2004). TNFǂ 
therefore aggravates edematous changes and suppresses the fibrotic response of the tissue. 
Moreover, ADM was shown to reduce endothelial hyperpermeability induced by hydrogen 
peroxide, thrombin, and Escherichia coli hemolysin (Hippenstiel et al., 2002). 
Two research groups reported recently that ADM signaling deficiency in mice resulted in 
midgestation death and massive edema. The cause of this edema was shown to be a result of 
fragility and hyperpermeability of blood vessels in one group and to be a failure of 
lymphatic vessel growth in the other (Ichikawa et al., 2008; Fritz et al., 2008). The evidence 
from these studies suggests that ADM plays an important role in preventing edema. From 
these observations, we speculate that ADM not only suppresses the production of TNFǂ, but 
also directly and indirectly inhibits edematous changes in the inflamed joint. 
Although RA is a chronic and systemic inflammatory disorder of unknown etiology, TNFǂ 
has been shown to play a central role in the pathogenesis of RA (Moreland et al., 1997; 
Elliott et al., 1993; Arend et al., 1995). TNFǂ stimulates the proliferation of synovial cells and 
the production of matrix metalloproteinases by chondrocytes and synovial cells, and 
induces the release of other proinflammatory cytokines, leading to joint destruction (Arend 
et al., 1995; Nishimoto et al., 2000). We have shown that daily injections of ADM into the 
knee joint spaces of rabbits with AIA suppressed the expression of TNFǂ mRNA in the 
synovial tissue in a dose-dependent manner (Fig. 15a). It has been reported that ADM 
suppressed the secretion of TNFǂ from lipopolysaccharide-stimulated RAW 264.7 
macrophages and NR8383 macrophages (Wong et al., 2005; Kubo et al., 1998; Wu et al., 
2003). Because the major source of TNFǂ in inflamed synovial tissue of RA is due to 
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macrophages (Chu et al., 1991) it is plausible that ADM suppresses the production of TNFǂ 
from activated macrophages in inflamed synovial tissue. 
On the contrary, we found that ADM increased IL-6 mRNA expression in the synovial tissue 
(Fig.15b). Our results agree with previous findings on the effects of ADM on IL-6 
production. ADM is reported to augment the production of IL-6 from NR8383 cells and 
Swiss 3T3 fibroblast cells stimulated with lipopolysaccharide or cytokines (Isumi et al., 
1998). Several observations support the concept that IL-6 is an anti-inflammatory cytokine 
(Tilg et al., 1997). IL-6 has been shown to have a suppressive effect on TNFǂ and IL-1ǃ 
production in peripheral blood mononuclear cells and exerts its anti-inflammatory effects in 
hepatitis by reducing the production of TNF (Schindler et al., 1990; Mizuhara et al., 1994). 
Our results therefore lead us to speculate that the mechanism involved in the anti-
inflammatory effects of ADM is related to suppression of TNFǂ in inflamed synovial tissue 
directly or through IL-6 production. 
Overproduction of IL-6 has been observed and is known to cause unfavorable clinical 
symptoms in immune-inflammatory diseases such as RA. Overproduction of IL-6 induces 
the production of rheumatoid factors and increases antibody levels, the platelet count, C-
reactive protein levels, and serum amyloid A protein levels in RA (Nishimoto et al., 2000). 
Treatment with a humanized anti-IL-6 receptor antibody has also been shown to reduce RA 
disease activity (Nishimoto et al., 2004). The effect of ADM on IL-6 production might 
therefore be an undesirable adverse effect in RA therapy. Plasma ADM levels have been 
reported to increase with RA disease activity and in the acute or flare phase of myocardial 
infarction and sepsis (Chosa et al., 2003; Yudoh et al., 1999; Kobayashi et al., 1996; Hirata et 
al., 1996). Recent studies have shown that ADM administration in the acute phase reaction 
of several disease models produced significant protective effects in organs against 
inflammation and oxidative stress (Kawai et al., 2004; Nakamura et al., 2004; Yang et al., 
2002). Miyashita and colleagues reported that ADM administration to prevent ischemic 
brain damage in mice less than 72 hours after the ischemic event showed significant 
therapeutic effects, whereas ADM administration more than 72 hours after stroke onset 
produced no significant therapeutic effects (Miyashita et al., 2006). 
From these observations and our study findings, we speculate that the effects of ADM 
may be dependent on the tissue environment and the disease state; that is, the role and 
effects of ADM in inflammation may change during the inflammatory process. ADM acts 
as a strong anti-inflammatory agent in the acute or flare phase of inflammation, but in the 
chronic phase of inflammation ADM may act not only as an anti-inflammatory agent but 
also as a proinflammatory agent. It is therefore important to consider the time of 
administration, the route of administration and the dosage schedule of ADM in the 
treatment of RA. 
5. Conclusions 
In our study, plasma ADM level was found to be elevated in patients with RA and the 
origin of ADM was shown to be synovial tissue. ADM may exert anti-inflammatory effects 
because the cultured RA synoviocytes secrete ADM, have ADM receptors, and inhibit IL-6 
production. Therefore, the effects of daily intra-articular injections of ADM into the knees of 
rabbits with AIA were examined. The results suggest that ADM suppresses the 
inflammatory response in inflamed joints by inhibiting the expression of TNFǂ mRNA and 
increasing IL-6 mRNA level. 
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Although ADM may have anti-inflammatory properties, the effect of ADM on IL-6 
production in inflamed synovial tissue might be an undesirable adverse effect in RA 
therapy. Further research is necessary to investigate the drug effects, the time of 
administration, and the dosage schedules of intra-articular injection of ADM in the 
treatment of RA.  
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